Genferon suppositories vagin.-Recto. 55mg + 10mg + 1000000me 10 pc

$17.20

Genferon suppositories vagin.-Recto. 55mg + 10mg + 1000000me 10 pc

Quantity:

Description

Composition
Active substance:
1 suppository for dosages of 55 mg + 250 000 IU + 10 mg, 55 mg + 500 000 IU + 10 mg, 55 mg + 1 million IU + 10 mg respectively contains: active substance: interferon alpha-2b human recombinant (rchIFN alpha 2b – 250,000 IU, 000 IU or 500 or 1 million IU; taurine – 0.01 g benzocaine – 0.055 g ;.
Excipients:
Hard Fat – sufficient quantity to yield 1.65 g of the suppository mass, dextran 60 000 – 0.0015 g Macrogol 1500 – 0.1240 g of polysorbate 80 – 0.0330 g, emulsifier T2 – 0.1320 g Sodium hydrocitrate – 0.0001 g of citric acid – 0.0015 g purified water – 0.0660 g
Description:
Suppositories white or white color with a yellowish shade, a cylindrical shape with a pointed end, in a longitudinal section homogeneous. On the cut tolerance of air core or funnel-shaped depressions.
Product form:
Suppositories 55 mg + 250 000 + 10 IU mg, 55 mg + 500 000 + 10 IU mg, 55 mg + 1000 000 + 10 IU mg.
5 suppositories in blisters of aluminum foil or PVC film. 1 or 2 blisters together with instructions for use in a stack of cardboard.
Contraindications
Individual intolerance to interferon and other substances that make up the drug.
Carefully.
Exacerbation of allergic and autoimmune diseases.
Dosage
55 mg + 1 million IU + 10 mg
Indications
In the complex therapy in infectious and inflammatory diseases of the urogenital tract in adults: genital herpes, chlamydia, ureaplasmosis, mycoplasmosis, recurrent vaginal candidiasis, bacterial vaginosis, trichomoniasis, human papillomavirus infection, bacterial vaginosis, cervical erosion, cervicitis, vulvovaginitis, Bartolini, adnexitis, prostatitis , urethritis, balanitis, balanoposthitis.
In the complex treatment of acute bronchitis in adults.
In the combined therapy of chronic recurrent cystitis bacterial etiology in adults.
Interaction with other drugs
GENFERON® most effective in combination with drugs (including antibiotics and other antimicrobial drugs), used in the treatment of urogenital diseases. Non-narcotic analgesics and anticholinesterase drugs enhance the effect of benzocaine. Benzocaine reduces the antibacterial activity of sulfonamides.
Overdose
Cases of drug overdose GENFERON® were reported. When a random one-time introduction of a larger number suppositories than prescribed physician should suspend further administering for 24 hours, after which the treatment can be resumed on the prescribed pattern.
pharmachologic effect
Pharmacological group:
Immunomodulating agents, interferons.
Pharmacodynamics:
GENFERON® – combined formulation, the effect of which is due to components in its composition. It provides local and systemic effects.
The composition Genferon® preparation includes recombinant human interferon alpha-2b, produced by bacterial strain Escherichia coli, in which genetic engineering techniques introduced gene of interferon alpha-2b human.
Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects. The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit the replication of viruses. Immunomodulatory effects manifested, first of all, increased cell-mediated immune reactions, which increases the efficiency of the immune response against viruses, intracellular parasites and cells which have undergone a neoplastic transformation. This is achieved by activation of CD8 + killer T cells, NK-cells (natural killer cells), enhancing differentiation of B-lymphocytes and production of antibodies, activation of the monocyte-macrophage system and phagocytosis as well as increasing the expression of molecules of the major histocompatibility complex I type, which increases the likelihood recognition of infected cells by cells of the immune system. Activation of leucocytes under influence of the interferon contained in all mucosal layers provides them with an active part in the elimination of lesions; In addition, due to the effect of interferon is reached secretory immunoglobulin product recovery A.
The antibacterial effect is mediated by the immune system enhanced by the influence of interferon.
Taurine contributes to the normalization of metabolic processes and tissue regeneration, has a membrane and immunomodulatory effects. As a potent antioxidant, taurine interacts directly with the active oxygen species, an excessive accumulation of which promotes the development of pathological processes. Taurine helps to preserve the biological activity of interferon, enhancing the therapeutic effect of the drug.
Benzocaine (benzocaine) is a local anesthetic. It decreases cell membrane permeability to sodium ions displace calcium ions from the receptors located on the inner surface of the membrane, blocking the conduction of nerve impulses. It prevents the emergence of pain impulses in the sensory nerve endings and the conduct of the nerve fibers. It has only a local effect, without being absorbed into the systemic circulation.
Pharmacokinetics:
With rectal administration it has a high bioavailability (80%) of interferon in connection with what is achieved by both local and systemic pronounced immunomodulating action; in intravaginal application due to the high concentration in the infected site and fixing the mucosal cells achieved a pronounced local antiviral, antiproliferative and antibacterial effect, with systemic effect due to low suction capacity of the vaginal mucosa is negligible. The maximum concentration of interferon in serum is reached after 5 hours after drug administration. The main route of excretion is an alpha interferon renal catabolism. half-life is 12 hours, which necessitates the use of the drug, 2 times a day.
Pregnancy and breast-feeding
Shows the use of normalization of local immunity at 13-40 weeks of pregnancy in the complex therapy of genital herpes, chlamydia, ureaplasmosis, mycoplasma, cytomegalovirus infection, human papillomavirus infection, bacterial vaginosis if there is itching, discomfort and pain in the lower parts of the urogenital tract.
Clinical studies have proven the safety of intravaginal drug application Genferon® 250,000 IU during pregnancy 13-40 weeks. Safety of the drug in the I trimester of pregnancy has not been studied.
Conditions of supply of pharmacies
On prescription.
side effects
The drug was well tolerated by patients. Possible local allergic reactions (burning sensation in the vagina). These phenomena are reversible and disappear within 72 hours after cessation of administration. Continued treatment may, after consultation with the doctor.
There may be problems arising from the application of all types of interferon alfa-2b, such as chills, fever, fatigue, loss of appetite, muscle and headaches, joint pain, sweating, and leukopenia and thrombocytopenia, but most often they are found in excess a daily dose of more than 10 million IU. To date, no serious adverse events were observed.
As with any other alpha-2b interferon preparation, in the case of temperature increase after single dose administration possible paracetamol at a dose of 500-1000 mg.
special instructions
To prevent re-infection of the urogenital encouraged to consider the simultaneous treatment of sexual partners.
Permitted use of the drug during menstruation.
GENFERON® drug does not affect the performance of potentially hazardous activities that require attention and fast reactions (vehicle control, machinery, etc.).
Storage conditions
At a temperature of 2 to 8 ° C.
Keep out of the reach of children.
Dosing and Administration
1. Infectious and inflammatory diseases of the urogenital tract in women.
1 suppository (250 000 ME or ME 500 000 or 1 million IU depending on the severity of the disease) rectally or vaginally (depending on the nature of the disease), 2 times a day every day for 10 days. In protracted forms 3 times a week, every other day 1 suppository for 1-3 months. When expressed infectious inflammation of the vagina may use 1 suppository 500,000 IU intravaginally morning and 1 suppository 1,000,000 IU rectally overnight simultaneously with the introduction into the vagina suppository containing antibacterial / antifungal agents. For the normalization of the local immunity in the treatment of infectious and inflammatory diseases of the urogenital tract in women during pregnancy 13-40 weeks of use 1 suppository 250 000 IU vaginal 2 times a day every day for 10 days.
2. Infectious-inflammatory diseases of the urogenital tract in men. Rectally 1 suppository (500 000 ME or ME 1,000,000 depending on the severity of the disease), 2 times a day for 10 days.
3. In the complex treatment of acute bronchitis in adults.
1 suppository (1,000,000 I.U.) 2 rectally twice a day for 5 days.
4. In the complex therapy of chronic recurrent cystitis in adults.
During exacerbation – 1 suppository (1,000,000 I.U.) rectally 2 times a day for 10 days in combination with a standard course of antibacterial therapy, followed by 1 suppository (1,000,000 I.U.) rectally every other day for 40 days with the aim of preventing relapse .
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

OTISIFARM

There are no reviews yet.

Add your review